Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

被引：1
|
作者：
Zhang, Yue [1 ]
Wu, Shenhong [1 ]
机构：
[1] Stony Brook Univ Hosp, Div Hematol & Oncol, Stony Brook, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
OPEN-LABEL; MULTICENTER; NIVOLUMAB;
D O I：
10.21037/tcr.2019.06.39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S585 / S588
页数：4
相关论文
共 50 条
  • [1] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Motzer, Robert J.
    Penkov, Konstantin
    Haanen, John
    Rini, Brian
    Albiges, Laurence
    Campbell, Matthew T.
    Venugopal, Balaji
    Kollmannsberger, Christian
    Negrier, Sylvie
    Uemura, Motohide
    Lee, Jae L.
    Vasiliev, Aleksandr
    Miller, Wilson H., Jr.
    Gurney, Howard
    Schmidinger, Manuela
    Larkin, James
    Atkins, Michael B.
    Bedke, Jens
    Alekseev, Boris
    Wang, Jing
    Mariani, Mariangela
    Robbins, Paul B.
    Chudnovsky, Aleksander
    Fowst, Camilla
    Hariharan, Subramanian
    Huang, Bo
    di Pietro, Alessandra
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1103 - 1115
  • [2] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    Szczylik, Cezary
    Markus, Maurice
    McDermott, Raymond S.
    Bedke, Jens
    Tartas, Sophie
    Chang, Yen-Hwa
    Tamada, Satoshi
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
  • [3] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [4] Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Uemura, Motohide
    Tomita, Yoshihiko
    Miyake, Hideaki
    Hatakeyama, Shingo
    Kanayama, Hiro-omi
    Numakura, Kazuyuki
    Takagi, Toshio
    Kato, Tomoyuki
    Eto, Masatoshi
    Obara, Wataru
    Uemura, Hirotsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Fujii, Yosuke
    Kamei, Yoichi
    Umeyama, Yoshiko
    Di Pietro, Alessandra
    Oya, Mototsugu
    CANCER SCIENCE, 2020, 111 (03) : 907 - 923
  • [5] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [6] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Axitinib in advanced renal-cell carcinoma
    Yousaf, Nadia
    Larkin, James
    LANCET ONCOLOGY, 2013, 14 (13): : 1245 - 1246
  • [8] Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
    Motzer, Robert J.
    Robbins, Paul B.
    Powles, Thomas
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Mu, Xinmeng Jasmine
    Ching, Keith A.
    Uemura, Motohide
    Pal, Sumanta K.
    Alekseev, Boris
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae Lyun
    Hariharan, Subramanian
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Donahue, Amber C.
    Choueiri, Toni K.
    NATURE MEDICINE, 2020, 26 (11) : 1733 - +
  • [9] Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
    Robert J. Motzer
    Paul B. Robbins
    Thomas Powles
    Laurence Albiges
    John B. Haanen
    James Larkin
    Xinmeng Jasmine Mu
    Keith A. Ching
    Motohide Uemura
    Sumanta K. Pal
    Boris Alekseev
    Gwenaelle Gravis
    Matthew T. Campbell
    Konstantin Penkov
    Jae Lyun Lee
    Subramanian Hariharan
    Xiao Wang
    Weidong Zhang
    Jing Wang
    Aleksander Chudnovsky
    Alessandra di Pietro
    Amber C. Donahue
    Toni K. Choueiri
    Nature Medicine, 2020, 26 : 1733 - 1741
  • [10] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345